| A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas (NCT05415072) | Novartis Pharmaceuticals | 2022-07-04 |
| An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma (NCT05022901) | Delcath Systems Inc. | 2022-06-10 |
| Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma (NCT05170334) | H. Lee Moffitt Cancer Center and Research Institute | 2021-12-15 |
| Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors (NCT05075993) | M.D. Anderson Cancer Center | 2021-11-12 |
| Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases (NCT04728633) | Thomas Jefferson University | 2021-09-27 |
| FHD-286 in Subjects With Metastatic Uveal Melanoma (NCT04879017) | Foghorn Therapeutics Inc. | 2021-05-11 |
| Communicating With Patients on Cancer Resistance to Treatment: the Development of a Communication Tool. (HECTOR) (NCT04118062) | Institut Curie | 2021-02-02 |
| Defactinib and VS-6766 for the Treatment of Patients With Metastatic Uveal Melanoma (NCT04720417) | Thomas Jefferson University | 2021-01-26 |
| Nivolumab Plus Relatlimab in Patients With Metastatic Uveal Melanoma (NCT04552223) | Jose Lutzky, MD | 2020-11-10 |
| Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions (NCT03947385) | IDEAYA Biosciences | 2019-06-28 |
| Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver (NCT03472586) | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 2018-05-02 |
| Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease (NCT03025256) | M.D. Anderson Cancer Center | 2018-05-02 |
| Efficacy Study of Pembrolizumab With Entinostat to Treat Metastatic Melanoma of the Eye (NCT02697630) | Vastra Gotaland Region | 2018-02-21 |
| Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma (NCT03068624) | M.D. Anderson Cancer Center | 2017-09-08 |
| Trial of Radiation and Gene Therapy Before Nivolumab for Metastatic Non-Small Cell Lung Carcinoma and Uveal Melanoma (NCT02831933) | Eric Bernicker, MD | 2017-02-15 |
| Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma (NCT01814046) | National Cancer Institute (NCI) | 2013-03-01 |
| Nivolumab and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma (NCT01585194) | M.D. Anderson Cancer Center | 2012-11-29 |
| Vorinostat in Treating Patients With Metastatic Melanoma of the Eye (NCT01587352) | National Cancer Institute (NCI) | 2012-05-29 |
| Efficacy and Safety Study of GSK1120212, a MEK Inhibitor, in Subjects With Uveal Melanoma (NCT01328106) | GlaxoSmithKline | 2010-11-01 |
| A Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma (NCT01551459) | The Clatterbridge Cancer Centre NHS Foundation Trust | 2010-10-01 |
| A Study to Assess PV-10 Chemoablation of Cancer of the Liver (NCT00986661) | Provectus Biopharmaceuticals, Inc. | 2009-10-01 |